PG Health's gummies drove a goldrush quarter with 30% PAT growth
Livogen Iron Gummies topped Amazon rankings and helped flagship brands Neurobion and Livogen grow 20% each, as preventive health trend accelerates.
What's new
- FY26 revenue ₹1,400 cr, up 16% YoY
- Profit after tax ₹327 cr, up 30% YoY
- Three innovation launches all exceeded expectations
- Distribution network expanded by ~30,000 pharmacies over 2-3 years
Themes from the call
Demand
VMS category steady growth; gummy format gaining traction, with Livogen Gummies #1 on Amazon addressing iron deficiency in 1-in-2 Indian women.
Margins
Gross margin expanded via ₹35 cr productivity savings, favorable product mix from innovation launches, and NPPA-aligned pricing up to 10%.
Capital allocation
Distribution transformation added ~30,000 pharmacies; international business growing (Nepal 3x growth, Sri Lanka high single-digit). No FY27 guidance offered.
Guidance watch
- Management declined to provide FY27 numerical targets, citing strategic confidentiality.
Risk flags
- E-pharmacy competition increasing with platforms like 1MG, Pharmeasy, Netmeds; GLP-1 treatments (Semaglutide) require differentiation positioning.
- New category entrants in probiotics and protein supplements present alternative consumption vectors.
Key quotes
-
"For the 12-month fiscal year ended March 31, 2026, we reported sales of close to Rs 1,400 crores, which is up 16% versus the comparable period last year. The profit after tax was Rs 327 crores, which is up by 30% versus the comparable period last year."
— Milind Thatte, Management
The brief
PG Health's innovation bet paid off. The company's three major launches — Livogen Iron Gummies, Neurobion Nerve Pain Cream, and Evion LC 1000 — all exceeded expectations in their first year, contributing early single-digit growth points to the business. The standout was Livogen Gummies, which seized the growing gummy format trend and hit #1 on Amazon in its category. That direct-to-consumer win signals that PG Health can build new consumption occasions around existing brands.
The numbers back the story. FY26 revenue hit ₹1,400 cr, up 16%, while PAT grew faster at 30% to ₹327 cr. Profit improvement came from productivity savings of ₹35 cr across operations, a favorable mix shift from innovation launches, and NPPA-allowed pricing increases. SG&A was reinvested into demand generation: consumer communication reached 14 million people with high single-digit ad recall, and HCP medical education touched 1 lakh doctors.
Distribution transformation also contributed. Over 2-3 years, the company added roughly 30,000 pharmacies and HCP touchpoints in extra-urban areas. That expansion, combined with a medically trained sales force, is enabling deeper penetration ahead of category growth. E-commerce and e-pharmacy channels are now material, with gummy formats gaining disproportionate traction online.
International business is emerging. Nepal exports grew 3x, Sri Lanka high single-digit, driven by Neurobion and Evion launches. Management confidence is high, rooted in brand fundamentals and the preventive health integration trend. But guidance remains opaque: no FY27 numerical targets were offered.
The risk is competitive. E-pharmacy platforms are investing heavily in user acquisition. GLP-1 drugs are a separate category that could shift supplement priorities. And new entrants in probiotics and protein supplements create alternative vectors for health spend. PG Health's science-backed positioning and HCP engagement model could defend against these, but the battle for the preventive health wallet is only intensifying.
Verdict: PG Health is executing well on innovation and distribution. The gummy goldrush is real, but the long game depends on sustaining the innovation pipeline and navigating a more crowded e-commerce landscape.
PG Health's gummy-led innovation is delivering growth and profit improvement, but the preventive health tailwind is not without competition.